RBC Downgrades Cephalon (CEPH) Following Cinquil Trial Results; Sees 'Little Momentum' Behind the Stock
Tweet Send to a Friend
Shares of Cephalon (Nasdaq: CEPH) have tumbled more than 9% today amid concerning initial results from a Phase IIb/II trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
